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Production of glycoconjugate vaccines involves the chemical conjugation of glycans to an immunogenic 
carrier protein such as Cross-Reactive-Material-197 (CRM197). Instead of using glycans from natural 
sources recent vaccine development has been focusing on the use of synthetically defined minimal 
epitopes. While the glycan is structurally defined, the attachment sites on the protein are not. Fully 
characterized conjugates and batch-to-batch comparisons are the key to eventually create completely 
defined conjugates. A variety of glycoconjugates consisting of CRM197 and synthetic oligosaccharide 
epitopes was characterised using mass spectrometry techniques. The primary structure was assessed by 
combining intact protein MALDI-TOF-MS, LC-MALDI-TOF-MS middle-down and LC-ESI-MS bottom-up 
approaches. The middle-down approach on CNBr cleaved glycopeptides provided almost complete 
sequence coverage, facilitating rapid batch-to-batch comparisons, resolving glycan loading and 
identification of side products. Regions close to the N- and C-termini were most efficiently conjugated.
Pathogens such as bacteria and parasites exhibit specific glycan structures on their surface1. These accessible bio-
molecules are targets for pathogen specific vaccination. Glycoconjugate vaccines that combine a glycan antigen 
with a carrier protein have for the most part replaced polysaccharide vaccines that fail to induce a strong immune 
response2 and do not result in B-cell memory in infants under the age of two3,4.
Successful and broadly marketed carbohydrate conjugate vaccines are based on just a few FDA-approved 
carrier proteins. First-generation carrier proteins such as diphtheria toxin and tetanus toxin require 
detoxification with formaldehyde eliminating part of the lysine residues needed for glycan attachment, 
thereby limiting conjugation efficacy5. One of the most widely used and highly effective carrier protein is 
Cross-Reactive-Material-197 (CRM197), a mutant version of the diphtheria toxin, where the single amino acid 
exchange of a glycine in position 52 to a glutamic acid renders the protein non-toxic6. Conjugate vaccines such 
as HibTITER® (Haemophilus influenzae type b associated diseases), Prevnar™ (pneumococcal diseases), and 
Menveo® (meningococcal diseases)7 use CRM197 as carrier protein.
Almost all currently marketed glycoconjugate vaccines contain isolated, large and heterogeneous glycans8,9. 
These vaccines are very successful, but technically, the isolation from natural sources is challenging. Not all 
pathogenic organisms can be grown to produce antigenic carbohydrates in vitro. Culturing and processing large 
amounts of human pathogens safely is complex and cost intensive. Downstream processing inevitably produces 
heterogeneous glycan mixtures of various lengths and modifications that are difficult to characterise before and 
after conjugation. In some cases, glycan processing can affect epitope integrity10,11. Regular in-depth molecu-
lar level characterisation of the final product that will be used for immunisation is thus not possible for these 
biologics.
The chemical synthesis of the immunogenic glyco-epitopes12 holds many advantages but only one 
semi-synthetic glycoconjugate vaccine (Quimi Hib) is currently on the market13. Synthetic, minimal 
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immunogenic glyco-epitopes are structurally well-defined and homogenous14. The synthetic approach enables 
the placement of a spacer carrying a unique functional group such as an amine to facilitate protein attachment at 
a single site without further activation.
Typically, glycans are coupled to the primary amine side chains of lysine residues and to the protein 
N-terminus via a linker molecule. Alternatively, sulfhydryl groups in cysteine or carboxyl side chains can serve as 
sites for attachment. Prior to coupling, non-synthetic glycans need to be activated15 either arbitrarily on hydroxyl 
or carboxyl groups16, leading to attachment at various points or via a single amine group, introduced by reductive 
amination, at the reducing end17. The choice of the linker is crucial since it influences vaccine properties18 and 
may be immunogenic itself19. In addition, coupling efficiencies have to be considered. Conjugation of a synthetic 
glyco-epitope to a carrier protein such as CRM197 that contains 40 primary amine side chains will result in heter-
ogeneous glycoconjugates since some amino acid side chains more readily engage in conjugation reactions than 
others20. Since variations in epitope loading influence the effectiveness of vaccines21,22 understanding which side 
chains preferentially react with glycans represents an important step towards producing better defined, more 
effective and safer conjugate vaccines. Quality control and batch-to-batch comparison relies on a combination 
of physicochemical, spectroscopic and spectrometric methods such as nuclear magnetic resonance (NMR) or 
mass spectrometry (MS)23–25. Glycan attachment to the carrier protein is typically monitored by SDS-PAGE and 
MALDI-TOF-MS26. These methods provide information about average loading and cannot detect any side reac-
tions or alterations occurring on the glycan epitopes. New methods are necessary for quality assurance of conju-
gate vaccines and to define conjugation sites on the protein.
We established a mass spectrometry-based assay for the in-depth characterisation of glycoconjugates obtained 
by coupling synthetic glycans to CRM197 (Fig. 1). An integrated new middle-down LC-MALDI-TOF-MS 
approach simplified batch-to-batch comparison, and enabled relative quantification of regional conjugation effi-
cacy. In this study we evaluated the influence of glycan size and amino acid microenvironment on conjugation 
efficiencies, assessed glycan integrity and determined which amino acid sites were preferably conjugated. Two 
regions close to the N- and C-termini of the protein engage primarily in the chemical conjugation process and 
exhibited the highest loading ratios. In addition to accessibility, our data clearly illustrates that the local amino 
acid environment significantly influences which lysine residues will be modified.
Results and Discussion
Protease based bottom up strategies for the evaluation of CRM197 glycoconjugate vaccine can-
didates. Assuring glycan integrity of the glycoconjugate is important after the chemical conjugation step and 
to evaluate the storage stability. We studied this property by a classical (glyco)proteomics bottom up approach, 
which provided qualitative data on individual, repeatedly conjugated sites in CRM197.
Figure 1. Schematic overview of the three orthogonal approaches employed for the in-depth 
characterisation of CRM197 conjugated with defined synthetic minimal glycoepitope vaccine candidates. 
Step 1: The glycan part is synthesised with a spacer carrying an amine group. Step 2: addition of the linker 
molecule with two leaving groups (LG). Step 3: addition of the glycan linker construct to the carrier protein and 
subsequent conjugation to a primary amine (e.g. lysine residue).
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For unmodified CRM197 the use of trypsin resulted in an average sequence coverage of 50–67%. Using 
Glu-C usually 50% of the entire sequence could be identified (see Supplementary Fig. S2). The highest coverage 
(≈ 70–85%) was obtained using a sequential digestion employing Glu-C followed by trypsin or Asp-N followed 
by Glu-C. Nevertheless, the results varied considerably from digest to digest indicating the limitation of such a 
bottom-up approach for routine analyses of chemically glycosylated neoglycoproteins.
Trypsin did not cleave at modified lysine residues resulting in conjugated peptides carrying at least one missed 
cleavage site27. As a result, the C-terminal lysine in any tryptic peptide had to be unmodified in order to be 
cleaved. This facilitated the assignment of the actual conjugation site in particular as for most glycopeptides 
only one lysine residue remained as a possible site of conjugation. On the other hand, the modification induced 
missed cleavage sites lead to an increased heterogeneity of peptide fragments and consequently reduced signal 
intensities.
The problem could be avoided by the use of alternative proteases not cleaving at lysine residues (Glu-C, 
Asp-N). However, these proteases produced peptides with multiple lysine residues. In order to elucidate the con-
jugation sites it was crucial to acquire sufficient sequence information from the MS/MS experiment. Besides the 
qualitative data an in-depth conjugation site analysis also required quantitative information on site occupancy. 
The protease assisted bottom-up approach, however, primarily provided qualitative data since a direct mass spec-
trometric quantitative comparison between different peptide backbones is impossible. Despite the fact that in 
some cases the conjugation reactivity of individual lysine residues located on the same peptide could be deter-
mined (Fig. 2D), a protease based approach appeared to be unsuitable for any broad quantitative comparison of 
region/site specific conjugation efficiencies between different conjugate vaccines.
CRM197 neoglycopeptides exhibit unusual CID and ETD fragmentation patterns. Naturally 
occurring glycopeptides usually exhibit strong and specific oxonium ions when subjected to collision induced 
dissociation (CID)28,29. This feature is frequently applied to quickly filter glycopeptide spectra from the bulk 
of MS/MS data. However, CRM197 neoglycopeptides carrying the glyco-epitope constructs used in this study 
(Table 1) produced a different fragmentation pattern which exhibited an extremely prominent Y-ion series when 
subjected to CID while showing almost no or very low intensity oxonium ions (see Fig. 2B and Supplementary 
Fig. S3). Assuming that the majority of protons are associated with the peptide rather than with the glycan moi-
ety, it appears that the linker construct prevents the protons from effectively migrating to the glycan fragments, 
Figure 2. Conjugation site determination by tandem mass spectrometry. (A) After Glu-C digestion a doubly 
charged precursor ion corresponding to glycopeptide 242KAKQYLEE249 carrying an ST3 epitope was detected 
and selected for fragmentation by CID and ETD. The red labeled K indicates the site of conjugation identified by 
tandem MS. (B) CID fragmentation resulted in a prominent Y-ion series indicating the loss of glucuronic acid 
and glucose, but no significant peptide backbone fragments. (C) ETD fragmentation of the peptide backbone 
confirmed peptide identity as well as K242 as the site of conjugation. (D) Extracted ion chromatogram of 
doubly charged ions of unconjugated and conjugated peptide 242–249 showing the separation of isobaric 
conjugate products by C18 LC [overlay of m/z = 504.40 (unconjugated peptide, black line), 568.85 (peptide with 
conjugated linker, blue line) and 928.45 (peptide with conjugated glycan, red line)]. Despite the proximity of the 
two potential conjugation sites, K242 was more effectively conjugated.
www.nature.com/scientificreports/
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LINKER AND SPACER MOLECULES
Structure Abbreviation Composition Description
DSA C14H16N2O8
di-succinimido-adipate linker Leaving 
group: succinimide
PNP C18H16N2O8
Adipic acid p-nitro-phenol linker 
Leaving group: para-nitrophenol
C2 C2H6N 2 carbon unit spacer
C5 C5H12N 5 carbon unit spacer
Linker side product (depicted as present after conjugation)
Structure Abbreviation Composition Δ m/z Description
L C6H10O3 128.06 Adipic acid/free linker #
CONJUGATES (depicted as present after conjugation)
ST3 (GlcA)2(Glc)2-C2- DSA 847.80 Epitope from Streptococcus pneumoniae serotype 3
PS1 (Rha)2(Glc)3-C5-DSA 991.42 Epitope from Clostridium difficile





Table 1.  Overview on linker, spacer and glycan epitope constructs used in this study. Δ m/z: monoisotopic 
mass addition upon conjugation to a primary amine. Glc = glucose, Rha = rhamnose, GlcA = glucuronic acid, 
Hep = heptose, Man = mannose, Gal = galactose; # Conjugation of linker molecule and subsequent hydrolysis 
of the leaving groups results in the same product for DSA linker and PNP linker.
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resulting mostly in the detection of neutral loss fragments. This observed phenomenon appeared to be inde-
pendent of the length of the carbon spacer. Despite the lack of oxonium ions the observed Y-ions showed a 
characteristic serial neutral loss of each monosaccharide in the glycan chain. This feature was used to distinguish 
MS/MS spectra of conjugated peptides from unconjugated ones. CID analyses also enabled confirmation of the 
glyco-epitope integrity after conjugation to the protein.
Electron transfer dissociation (ETD) of the peptide backbone30 enabled the acquisition of sufficient data 
to confirm peptide identities and map the site(s) of conjugation on the majority of the detected glycopeptides 
(Fig. 2C). Nevertheless, the ETD MS/MS spectra derived from the CRM197 neoglycopeptides showed unusual 
fragmentation patterns. Z-ions were highly underrepresented, especially when obtained from tryptic glycopep-
tides. The c-ions series continued at most until the amino acid neighbouring the conjugated lysine, and z-ions 
containing this residue could generally not be detected.
Glyco-Epitope screening by nanoLC-ESI-MS/MS. Liquid chromatography enabled separation of iso-
baric modified peptides carrying the conjugate at different lysine residues. In addition to the glycoconjugates we 
detected conjugates of adipic acid formed by residual linker reacting with the lysine residues of CRM197. This is a 
common problem since the di-succinimido-adipate (DSA) linker hydrolyses very easily hampering an extensive 
purification. These adipic acid conjugation artefacts are referred to as "free linker" in this study. Addition of the 
glycan construct as well as of the free linker resulted in an increased retention time with the glycan-linker con-
struct showing the biggest impact (Fig. 2D).
Minor unintended structural features or contaminations might not always be picked up prior to conjuga-
tion. The multiple dimensions of nano LC-ESI-MS/MS analysis detected low abundant features such as a peptide 
carrying a minor side product of the chemical synthesis of ST3. CID fragmentation revealed that one of the two 
glucuronic acids of the tetrasaccharide was substituted by a glucose resulting in a mass shift of − 14 Da from the 
expected value (Fig. 3). This technique also allows detection and monitoring of any mass modification due to 
degradation.
Overall, the bottom up approach provided useful data to confirm conjugate integrity, to enable conjuga-
tion site mapping and to monitor site-specific conjugation preferences. Nevertheless, issues such as incomplete 
sequence coverage or the uncontrollable heterogeneity of proteolytic (glyco)peptide products31 made it less 
suited for ensuring batch-to-batch consistency of chemically glycosylated CRM197 in a pharmaceutical context. 
Therefore, an orthogonal LC-MALDI-TOF MS based approach was developed with the intention to overcome 
these shortcomings and enable fast batch-to-batch comparisons while still providing more detailed data on gly-
cosylation occupancy compared to intact protein analyses.
Improved CRM197-glycoconjugate sequence coverage using chemical cleavage combined 
with LC-MALDI-TOF-MS. We developed and applied an LC-MALDI-TOF-MS middle-down proteomics 
approach based on CNBr mediated cleavage to increase sequence coverage and simplify batch-to-batch compar-
isons while achieving a better general overview on the entire protein sequence detecting any intended and unin-
tended modifications. CNBr mediated protein cleavage results in larger glycopeptides that should compensate 
or significantly reduce ionisation suppression effects. Glycosylation was shown to reduce ionisation efficiency of 
tryptic N-glycopeptides, however ionisation efficiency appeared to increase when the peptide to glycan mass ratio 
was shifted towards the peptides32.
CNBr cleavage occurs on the C-terminal side of methionine residues33. In the case of CRM197 CNBr cleav-
age results in nine distinct (glyco)peptides for subsequent LC-MALDI-TOF-MS analysis (see Supplementary 
Table S4). Eight out of nine peptides could be reproducibly detected, corresponding to a sequence coverage 
of > 99% (Fig. 4). The missing four amino acid peptide (179YEYM182) exhibited a mass < 600 Da, which is below 
the optimal operation range of MALDI-TOF-MS. This particular peptide is one of two that do not carry any 
potential conjugation sites such as lysine residues or the protein's N-terminus, ultimately leaving only seven pep-
tides that needed to be considered in a simplified and comprehensive batch-to-batch comparison.
Due to the large size of the peptides C8- as well as C4-reversed phase LC were tested for (glyco)peptide sep-
aration. The C4-chromatography provided better peak shapes and separation reproducibility and was therefore 
Figure 3. MS spectra of the doubly charged precursor ions m/z = 787.90 and m/z = 780.92 as well as their 
respective CID MS/MS spectra. Using CID fragmentation even minor amounts of synthesis byproducts 
containing glucose instead of a glucuronic acid at the second position could be identified after being conjugated 
to CRM197.
www.nature.com/scientificreports/
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used for the majority of analyses. As expected, the most intense m/z signals corresponded to singly charged ions 
while larger peptides (m/z > 5000 Da) were detected as minor signals of doubly charged species as well (Fig 4).
Two batches of ST3 conjugate were analysed in a first run. Depending on their size, the peptides usually eluted 
during approx. 1–2 minutes. ST3 conjugated glycopeptides were detected by their specific mass shift of + 847.80 
Da, corresponding to the average mass of one glycoconjugate unit. A mass shift of + 128.06 Da indicated the 
presence of free linker.
The presence of conjugated adipic acid on a CNBr peptide resulted in a retention time shift of around + 30 sec-
onds whereas the presence of a glycoconjugate barely had any effect. In contrast, in the bottom up approach the 
separation of (glyco)peptides using C18 chromatography, free linker and especially glycoconjugates showed a 
much larger influence on retention time (Fig.  5). The survey view of the WARP-LC software allows for a simulta-
neous assay like representation of retention time, m/z and intensity. This provided a clear overview of the conju-
gation status of each CNBr cleaved (glyco)peptide. Increasing amounts of glycoconjugates as well as the addition 
of several adipic acid units could be easily depicted as characteristic peak patterns (Fig. 5).
SurveyViewer assisted comparison of batch-to-batch variances. Analyses of several batches of 
conjugates demonstrated that differences in loading and the extent of side reactions could be quickly detected in 
a protein region specific manner and evaluated using this approach. Major differences in free linker loading and 
consequently in glycan loading could be observed between the different conjugates (Fig. 5). Batch B showed one 
additional glycan conjugation in each of the peptides whereas batch A exhibited an increased free linker load-
ing. More detailed information was obtained when relative quantification of the respective (glyco)peptides was 
applied (Fig. 6). The degree of conjugation with the free linker differed considerably in the two batches. Batch A 
generally displayed an elevated loading. This increased occupation of lysine residues with free linker molecules 
resulted in a reduced number of available sites for glycan conjugation, explaining the observed lower glycan 
loading.
To address the issue of adipic acid conjugation onto the protein and further benchmark the assay a new set 
of CRM197 glycoconjugate was prepared using the p-nitrophenol (PNP) activation method34 with GLC as a test 
epitope (Table 1, Fig. 5). Compared to DSA, the PNP-linker is less prone to hydrolysis allowing an extensive puri-
fication after activation. The analysis showed that glycan loading was generally lower, however only conjugated 
glycans and no free linker molecules were detected in both batches. Our findings demonstrate the potential of the 
assay to reliably detect and differentiate intended and unintended modifications occurring on CRM197.
Evaluation of CNBr cleavage conditions on glycan conjugate integrity. CNBr cleavage requires 
highly acidic conditions (50% TFA). Even though the sample preparation is performed at low temperature (4 °C) 
the acidity could potentially affect glycan integrity. Therefore, we evaluated the stability of the glycan epitopes 
used in this study (Table 1). As exemplified on the ST3, PS1 and GLC-CRM197 conjugates no degradation 
Figure 4. Overlay of all LC-MALDI-MS spectra acquired during the LC run of unconjugated CRM197. 
For each identified peak charge, peptide position and average mass are indicated. The major peaks are all 
corresponding to the singly charged CNBr peptides without any missed cleavages. All of the eight expected 
peptides were detected. Doubly charged species were also found for larger peptides as well as low abundant 
signals corresponding to peptides with missed cleavage sites. The survey view illustrates retention time 
differences of the various peptides.
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products could be detected (Fig. 5). Our data indicate that most glycan structures appear to tolerate the applied 
cleavage conditions.
Conjugation site identification on CNBr glycopeptides using ISD. To determine site-specific 
attachment information from the conjugated glycopeptides we tested fragmentation by in source dissociation 
Figure 5. Comparison of conjugation efficiency on peptides 231–314 and 460–535 shown for four samples 
carrying different glycoepitopes. In the SurveyViewer (retention time vs. m/z) of a (C4) LC-MALDI-MS 
experiment (left) intensities of the detected signals are plotted vs. their retention times and signal intensities in a 
gel-like representation, providing a quick overview on the number of conjugates present on each CNBr peptide 
(right). Spectra obtained for peptide 460–535 at a given retention time. Samples conjugated with the DSA-
linker appeared in clusters with varying amounts of linker and glycoconjugates. Linker addition induced a shift 
of + 128 Da and minor shifts in retention time. A single glycoconjugate addition increased the mass by 848 Da 
(ST3), 333 Da (GLC), or 991 Da (PS1), respectively. Major differences in loading of free linker and glycans were 
easily detectable by this approach. ST3 batch-to-batch comparison revealed batch A containing up to one glycan 
conjugated to peptide 231–314 and up to two conjugated to peptide 460–535, whereas the loading was increased 
in batch B with up to two glycoconjugates attached to peptide 231–314 and up to three to peptide 460–535, 
respectively. The lower glycan loading in batch A correlated with stronger signals for linker conjugation. GLC 
was conjugated via a PNP-linker and showed no detectable free linker additions and therefore no clusters as 
seen for the DSA-conjugated peptides.
Figure 6. Relative quantitation of the seven lysine containing CNBr peptides derived from two ST3 
batches. Each peptide section was quantified individually. The sum of the area under the curve from all detected 
signals obtained for a given peptide (with and without modifications) was set to 100 %. The percentages 
presented in the graph are rounded to the full digit. Differences in glycan and free linker loading could be 
directly compared for each peptide. The results clearly demonstrated that glycan loading was more effective in 
batch B over the entire protein sequence. Inversely batch A exhibited higher loading of free linker molecules.
www.nature.com/scientificreports/
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(ISD) using this LC-MALDI-TOF-MS approach. This technique has been frequently used for N- and C-terminal 
protein sequencing of medium size and larger proteins35–37, and in the case of smaller proteins even top-down 
de novo sequencing of the entire protein was achieved38.
In order to assign the conjugated glycan to a specific lysine residue, the unconjugated peptide should ideally 
be LC baseline separated from the different conjugated forms. As mentioned previously in the text just minor 
retention time differences were observed and the necessary separation required for ISD was not achieved when 
using the C4 column. In contrast, C8 chromatography resulted in sufficient separation in the case of two singly 
conjugated (glyco)peptides. ISD analysis of these compounds allowed sequence confirmation of the individual 
peptides and assignment of the modification to the respective amino acid (Fig. 7).
Despite the LC separation it must be assumed that the selected m/z signals still contained a mixture of conju-
gation site isomers. Therefore, fragment ions specific for less abundant isomers are likely suppressed by the most 
intense glycopeptide isomer(s), providing information on the site(s) most efficiently modified within a glyco-
peptide. In peptide 231–314, K242 was identified as the most prominent conjugation site for both, conjugations 
with the free linker as well as with the glycan. A similar observation was made for K212 on peptide 183–230 (see 
Supplementary Fig. S5), indicating that these lysine residues are more frequently conjugated. These results also 
correlated well with the data obtained for K242 within peptide 242–249 after digestion with Glu-C (Fig. 2D) and 
demonstrate the principal applicability of ISD fragmentation to obtain in-depth attachment site information on 
chemically conjugated glycopeptides.
Evaluation of conjugation site occupancy. Even though CRM197 contains 39 lysine residues and the 
N-terminal amine that can serve as sites of conjugation, not all of them seem to be equally reactive. Steric acces-
sibility, the individual pKa of the respective lysine residues as well as reaction conditions and conjugate size are 
likely to influence the conjugation efficacy of individual sites. To evaluate whether particular lysine residues rep-
resent favoured sites of conjugation, various CRM197 conjugates (ST3, PS1, LPG and GLC, Table 1) were digested 
either with trypsin or orthogonal proteases and protease combinations. Thereby, a qualitative conjugation site 
map of all modified primary amines was established based on the presence of conjugation sites in the different 
samples (Fig. 8).
Three areas within CRM197 seem to be preferred for the attachment of glycan epitopes: In addition to lysines 
K37, K103, K104 and K125, a region including residues K212, K221, K227, K236 and K242 as well as the 
C-terminal part (in particular K498 and K526) were repeatedly found to be conjugated (Fig. 8). Some peptides 
such as the peptide 519DHTKVNSKLSLFFE532 containing K526 could only be detected using certain protease 
combinations. In terms of attachment sites the results are in good agreement with those from Crotti et al.20, who 
evaluated site reactivity based on the presence of a linker molecule without the glycan. In silico mapping of the 
lysine residues on a CRM197 structure model39 showed that most conjugation sites identified in the course of this 
work are located on outer edges (Fig. 8).
Figure 7. Exemplary MALDI-ISD spectra of CRM197 peptide 231–314 acquired from the unconjugated 
control (top) and an ST3 conjugated batch (bottom) after separation by C8 chromatography. An m/z + 848 
shift of the c12-ion observed between the top and bottom spectra indicated K242 to be the major modified lysine 
residue in this peptide. The ISD-spectra also provided extensive amino acid sequence data of the peptide.
www.nature.com/scientificreports/
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The conjugation of mono- to pentasaccharides as performed in this study as well as the conjugation of just 
a linker molecule as described by Crotti and colleagues did not show marked differences in conjugation site 
selectivity. Based on these data we conclude that smaller variations in conjugation efficiency observed within 
the different epitopes are in majority due to unavoidable batch-to-batch variations resulting from the chemical 
glycosylation protocol rather than induced by structural differences of the epitopes.
In contrast, the microenvironment of the conjugation site apparently influenced the conjugation efficiency 
significantly, as demonstrated in particular by glycopeptide 242KAKQYLEE249 obtained after Glu-C-digestion. 
The two lysine residues K242 and K244 are located within an alpha helical part in close proximity to each other 
but differed significantly in their respective conjugation reactivity. An exclusive steric effect is unlikely to account 
for the reactivity differences, however variations in the regional pKa of the respective lysine residues might be 
involved. Studies on helix stabilisation by glutamic acid and lysine residues showed that these amino acids, when 
spaced three to four amino acids apart, were efficiently stabilizing alpha helices by the formation of salt bridges40. 
Unlike K242, K244 is located in sufficient proximity to three glutamic acid residues (E240, E241, E248, Fig. S6) 
and could be involved in forming a salt bridge, stabilizing the positive charge of K244 and hence decreasing its 
nucleophilicity, rendering K244 less reactive.
Semi-quantitative regio-specific occupancy determination by LC-MALDI-TOF MS. The signal 
intensities of the unconjugated peptide and all of its modified forms detected in the LC-MALDI-TOF MS exper-
iments were summed up and the relative amounts for each peptide/glycopeptide group were determined. In 
the case of ST3 and PS1, peptides 15–115 and 460–535 were most efficiently conjugated, followed by peptides 
183–230 and 231–314 (Fig. 9A). Peptides 1–14, 116–178 and 340–469 were found to be least efficiently conju-
gated. A similar result was obtained for GLC-CRM197 conjugates that were produced via the PNP method, where 
no free linker interfered with the conjugation. Again, peptides 15–115 and 460–535 showed the lowest amount of 
Figure 8. (Left): Heatmap showing the lysine residues detected to be conjugated (red label) after proteolytic 
digestion with trypsin, Glu-C or combinations of trypsin/Glu-C or Glu-C/Asp-N. Grey labelled lysine 
residues were not observed as being conjugated. Data obtained for four independent conjugates carrying a 
variety of glycoepitopes (LPG, ST3, PS1 and GLC as represented in each column) showed that several lysine 
residues were commonly found conjugated. (Right) 3D crystal structure of CRM197 dimer (PDB entry: 4AE0). 
Lysine residues are labelled blue. Lysine residues that were frequently found conjugated with a glycan in all the 
samples are labelled in red.
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unconjugated peptide and the highest conjugate loading (Fig. 9B). Apart from peptide 1–15, the LC-MALDI-MS 
results for the least conjugated region are qualitatively correlating with the LC-ESI-MS data.
The data acquired using various orthogonal approaches in the course of this study allowed us to 
semi-quantitatively evaluate conjugation efficiency on the individual lysine residues. We concluded that amino 
acid residues K103, K498, and K526 were among the most reactive ones in the peptides 15–115 and 460–535, 
since these peptides showed the highest overall conjugation. In the slightly less reactive peptides 183–230 and 
231–314 amino acids K212, K221, K242 and K236 were among the frequently conjugated sites.
Conclusions
Characterisation of glycoconjugate vaccines requires sophisticated and orthogonal approaches. In the course 
of this study we applied well-established glycoproteomic techniques and developed a novel approach for the 
in-depth characterisation of the widely used immunogenic carrier protein CRM197 that was modified with a vari-
ety of defined synthetic oligosaccharide epitopes. Chemical cleavage using CNBr followed by a "middle-down” 
LC-MALDI-ISD detection strategy provided several advantages towards any protease based assays for compre-
hensive and in-depth semi-quantitative evaluation of region specific conjugation efficiency for CRM197 glycocon-
jugate vaccine candidates. This technique largely facilitated conjugation product screening by providing virtually 
complete sequence coverage, good overview on intended as well as unintended modifications and allowed a 
reproducible, protease independent opportunity for batch-to-batch evaluations. From the 40 possible primary 
amines (39 lysines + N-terminus) present in CRM197, just a few participate in quantitatively relevant conjugation 
reactions. Steric accessibility, the local amino acid environment and protein secondary structure are likely the 
most relevant parameters influencing the conjugation reaction under non-denaturing conditions. Our findings 
can ensure quality control of effective and safe vaccines as well as improving rational vaccine design in the future. 
It remains to be seen how conjugation variations on these specific sites possibly influence CRM197 conjugate 
vaccines effectiveness, nevertheless the presented assay provides an important step towards functional studies 
applying CRM197 glycoconjugate vaccine candidates carrying defined synthetic glyco-epitopes.
Figure 9. Quantitation results from LC-MALDI-MS measurements. (A) Quantitation of unconjugated 
peptides from of ST3 batch A, ST3 batch B and PS1 (only peptides containing lysine residues were taken into 
account). Peptides 15–115 and 460–535 show the lowest amounts of unconjugated peptide, consequently 
carrying larger amounts of glycoconjugates and/or free linker, indicating that conjugation was more efficient 
at lysine residues present in these peptides. (B) Quantitation of two batches of GLC (batch a and batch b) 
conjugated via the PNP-linker. Only glycan conjugates were found to be present on the peptides. Again, 
peptides 15–115 and 460–535 show the highest loading.
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Material & Methods
Reagents. Sequencing grade trypsin was purchased from Roche (Mannheim, Germany), Glu-C and 
Asp-N from Protea Bioscience (Morgantown, WV). Acetonitrile (ACN), formic acid (FA), trifluoroacetic 
acid (TFA), cyanogen bromide (CNBr), iodoacetamide (IAA), dithiothreitol (DTT), ammonium bicarbonate 
and triethylamine amine were purchased from Sigma Aldrich (Munich, Germany). Recombinant CRM197 was 
obtained from Pfenex (San Diego, CA). The BCA assay was purchased from Pierce (Rockford, IL), C18 ZipTips® 
and Cetricon® diafilters were purchased from Millipore (Tullagreen, Irland) and hydrophilic lipophilic balanced 
solid phase extraction cartridges 30 MG (HLB SPE) were obtained from Supelco/Sigma Aldrich (Bellefonte, PA). 
Generally, the MIAPE and MIRAGE reporting guidelines are followed throughout this work41,42.
Glycan epitope synthesis. The glycan epitopes ST3, PS1 and LPG (Table 1) were synthesised from mono-
saccharide building blocks as described previously43–45.
Synthesis of p-nitrophenol activated ester (GLC-PNP). The details on the synthesis of GLC-PNP are 
described in Supplementary Material S7.
DSA conjugation of synthetic glycans to CRM197. Oligosaccharide (3.46 μ mol) was dissolved in 100 μ L 
DMSO and added drop wise to a solution of 0.33 mmol of di-succinimido adipate in 100 μ L DMSO. Before the 
addition of glycan, a catalytic amount of triethylamine was added to the linker solution. After 2 hours 0.5 mL 
0.1 M phosphate buffer pH 7.4 was added to the reaction mixture and residual unreacted linker was extracted 
with 14 mL of Chloroform. The extraction procedure was repeated three times and the resultant aqueous layer 
was centrifuged (300 g, 5 min) to separate traces of chloroform. The resultant aqueous layer was added to 1 mL of 
protein solution (CRM197 1 mg/mL in 0.1 M phosphate buffer pH 7.4) and the reaction was allowed to continue 
for 5–6 hours with gentle stirring. The final reaction mixture was purified by ultrafiltration and the final protein 
concentration was determined by micro BCA assay following the manufacturer’s recommendations.
p-Nitrophenol (PNP) conjugation of synthetic glycans to CRM197. PNP half ester (172.4 nmol, 
4 μ g/μ L in DMSO) was added slowly to 17.24 nmol of CRM197 in 500 μ L of 0.1 M phosphate buffer pH 7.9 and 
allowed to react for 24 h at room temperature. After the reaction was complete, the protein was dialysed by diafil-
tration (30 kDa Centricon Diafilters). Conjugation efficiency was monitored by SDS-PAGE and MALDI-TOF MS.
Proteolytic Digestion. Protein (5 μ g) was added to 4 μ L of a 4x SDS-PAGE sample buffer (250 Mm 
Tris-HCl, 40% glycerine, 4% SDS, 0.015% Bromophenol blue containing 50 mM DTT) and denatured at 96 °C 
for 5 minutes before 0.5 μ L of 500 mM IAA were added to achieve a final concentration of 50 mM IAA. The solu-
tion was incubated 30 min in the dark before loading the protein onto a 10% SDS-PAGE gel for electrophoretic 
separation. Proteolytic digestion and peptide extraction were performed as described earlier28. Briefly, excised 
bands were cut into pieces destained in 50% ACN and dried. Proteases (Trypsin, Glu-C, Asp-N) were used in a 
protease to protein ratio of 1:50 respectively in the single digests or successively in double digests (Tryp/Glu-C; 
Glu-C/Asp-N). After peptide extraction with 2x 50% ACN and 2x 5% FA the samples were dried in a Speed Vac 
concentrator and reconstituted in 0.1% FA for further MS analysis.
Cyanogen bromide cleavage. One crystal of cyanogen bromide (CNBr) was dissolved in 200 μ L 50% TFA. 
10 μ g (30 μ g for larger amounts) of protein were dissolved in 190 μ L 50% TFA. Subsequently, 10 μ L of the CNBr 
stock solution were added. The solution was topped with N2, sealed with Parafilm and incubated for 48 hours 
at 4 °C in the dark. The reaction was quenched by the addition of 1 mL of water with subsequent removal of the 
liquid by Speed Vac drying. The sample was reconstituted in 10 μ L 0.1% FA and purified by C18 ZipTips eluting in 
10 μ L 80% FA. Larger amounts of initial protein were reconstituted in 50 μ L and purified by HLB SPE. The sample 
was washed three times with 400 μ L of 0.1% FA and peptides were eluted using three times 200 μ L 80% ACN con-
taining 0.1% FA. The sample was dried and reconstituted in 20 μ L of 0.1% TFA for LC-MALDI-TOF-MS analysis.
LC-ESI-MS/MS. NanoLC-ESI-MS analysis was carried out on an Ultimate 3000 RSLC-nano system (Dionex/
Thermo Scientific, Sunnyvale, CA) coupled to an amaZon speed ETD ion trap (Bruker, Bremen, Germany). In 
each run peptides corresponding to 0.15 μ g of a CRM197 digest were injected. The peptides were concentrated on a 
C18 precolumn (Acclaim PepMap100™ , Thermo, 100 μ m × 20 mm, 5 μ m particle size) and separated by reversed 
phase chromatography on a C18 analytical column (Acclaim PepMAp™ , Thermo, 75 μ m × 15 cm, particle size 
3 μ m). The samples were loaded in 99% buffer A (0.1% FA) for 6 min on the precolumn at a flow rate of 6 μ L/min 
before the captured peptides were subjected to nanoLC at a flowrate of 350 nL/min using a gradient of increasing 
ACN as follows: buffer B (ACN containing 0.1% FA) from 1% to 20% (7–57 min) followed by a further increase to 
50% (57–75 min) and a steep increase to 90% (75–86 min) before returning to the starting conditions. The mass 
spectrometer was set-up to perform CID as well as ETD fragmentation on the three most intense signals in every 
MS scan. An m/z range from 380–1800 Da was used for data dependent precursor scanning. The MS data was 
recorded using the instrument's "enhanced resolution mode". MS/MS data was acquired in "ultra-mode" over an 
m/z range from 100–2000. Details on the MS CID and ETD settings can be found as Supplementary Table S1.
LC-MALDI-TOF-MS analysis. LC-MALDI-TOF-MS experiments were performed on an ultrafleXtreme 
MALDI-TOF/TOF (Bruker, Bremen, Germany). Peptides were separated via an Agilent 1200 by C8 (Zorbax 
300SB-C8, 3.5 μ m, 100 × 0.3 mm from Agilent) and C4 (Phenomenex, Jupiter C4 300A, 150 × 0.3 mm) capillary 
reversed phase separation. Typically, 4–8 μ g of samples were injected. Buffer A was 0.1% TFA. Buffer B was ACN 
with 0.1% TFA. The 40 min gradient was as followed: Buffer B: 5–20% in 5 min and 20–55% over 30 min. Fractions 
of 3 μ L were spotted every 15 seconds by a PROTEINEER fc II on a MTP BigAnchor 384 MALDI-target (both 
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Bruker, Bremen, Germany). Super dihydroxybenzoic acid (sDHB) was used as matrix. Aliquots of 0.5 μ L of a 
50 mg/mL matrix solution in 50% ACN/water/0.1% TFA were spotted to each dried fraction.
The fractions were then analysed in an automated way by WARP-LC 1.3 and Compass 1.4 in positive linear ion 
mode and spectra were displayed according to their retention time in the SurveyViewer of the software. In-source 
decay (ISD) spectra were then manually acquired on selected fractions using a positive reflector method opti-
mised for ISD. Typically, 5000–10000 laser shots were accumulated for each ISD spectrum. External calibration 
of ISD spectra was performed with ISD fragments of bovine ubiquitin spotted on the calibration chips of the MTP 
384 BigAnchor target.
MS Data Processing. LC-MS data was analysed with Compass 4.1 analysis software (Bruker, Bremen, 
Germany). Compound spectra were created with a retention time window of 0.5 min and an intensity threshold 
of 100000. EIC for neutral loss of respective monosaccharide glycan masses were screened for conjugated pep-
tides as well as all compound spectra were checked manually for presence of conjugated peptides. Protein cov-
erage was evaluated using ProteinScape 3.1 (Bruker, Bremen, Germany) and the MS data was searched against a 
custom-made database using Mascot server 2.3 including all available entries for CRM and diphtheria toxin. The 
cleavage sites were defined as non-specific since some unspecific cleavage products were identified.
LC-MS data was analysed and the area under the curve (AUC) was quantified on SurveyViewer (Bruker). For 
quantitation AUC of the EICs of the respective peptide/glycopeptide signals was integrated. For each peptide the 
sum of all AUC of the modified forms and the non-modified peptides was set as 100%. The ISD spectra were pro-
cessed in Compass 4.1 using SNAP as peak picking algorithm for monoisotopic peak annotation and further ana-
lysed in BioTools 3.2 SR4 (Bruker). Peptide sequences were modified with the conjugates and matched with the 
ISD spectra to determine the modification sites. Each annotation was further validated manually. The mapping 
of the reactive lysine residues in the 3D model was performed using Molecular Operating Environment (MOE), 
2014.09 (Chemical Computing Group Inc., 1010 Sherbooke St. West, Montreal, QC, Canada).
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